Astrana Health Sees FY24 EPS $1.12-$1.36 Vs $1.42 Est.; Revenue $1.75B-$1.85B Vs $1.76B Est.
Astrana Health Sees FY24 EPS $1.12-$1.36 Vs $1.42 Est.; Revenue $1.75B-$1.85B Vs $1.76B Est.
2024 Guidance:
2024年指引：
Taking all of Astrana's recent growth initiatives and capital allocation strategy into account, the Company is updating its revenue, net income attributable to Astrana, and EPS - diluted guidance for 2024 while reiterating guidance for Adjusted EBITDA for the year ending December 31, 2024.
考慮到Astrana的所有最近的增長舉措和資本配置策略，該公司更新了其2024年營業收入、歸屬於Astrana的淨利潤和每股收益-攤薄指引，同時重申截至2024年12月31日的調整後EBITDA指引。額外信息請參見下面的「淨利潤與EBITDA和調整後EBITDA的指引對比」和「非GAAP財務指標的使用」。實際金額是否超出預期會產生重大影響，具體詳情請參見下面的「前瞻性聲明」。
| ($ in millions, except per share amounts) | 2024 Guidance Range | |||||||
| Low | High | |||||||
| Total revenue | $ | 1,750 | $ | 1,850 | ||||
| Net income attributable to Astrana Health, Inc. | $ | 54 | $ | 66 | ||||
| Adjusted EBITDA | $ | 165 | $ | 185 | ||||
| EPS – diluted | $ | 1.12 | $ | 1.36 | ||||
| （以百萬美元計，除每股數據外） | 2024年指導範圍 | |||||||
| 收盤最低價 | 高 | |||||||
| 總收入 | $ | 1,750 | $ | 1,850 | ||||
| Astrana Health，Inc.的淨利潤 | $ | 54 | $ | 66 | ||||
| 調整後的EBITDA | $ | 165 | $ | 185 | ||||
| 每股收益-攤薄 | $ | 1.12 | $ | 1.36 | ||||
See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
有關詳細信息，請參閱以下「淨利潤與EBITDA和調整後EBITDA的指引對比」和「非GAAP財務指標的使用」。不能保證實際金額不會顯著高於或低於這些預期。請參見下面的「前瞻性聲明」獲取更多信息。
